RE:20-day volume weighted average price Pof, we know you're an expert on these things, so, really, does the price of the financing, and whether Armistice has 56.6% of Biodexa or 66.6% of Biodexa, make any difference to Bioasis shareholders? I mean, the symbolism of that latter number notwithstanding?
It's been bothering me since the beginning, but if this deal collapses, who would benefit? It looks like Lind to me. Lind could force a default and acquire all of Bioasis's assets. That would get rid of those pesky Bioasis shareholders, and maybe even the Midatech and Armistice interests. Lind could then do anything it wants with xB3. But who would they sell it to? At what price?
To the highest bidder, free and clear of Bioasis, posssibly, unless there are other things afoot.
What if Lind is tied at the hip to Ladenburg Thalmann? Whose interests would LT then represent? Would they say to Bioasis, "Sorry about that" and then execute something with Lind, something that may or may not include Midatech?
Are Armistice and Midatech willing to pay Lind for xB3? Armistice might be willing to outbid Midatech. They could then have it all, no cumbersome public company to navigate around.
So if the financing is in Midatech's hands, if they can call off the financing at a certain trigger point, 90¢, would they do it? I suspect they would do the financing at almost any price. The 20-day VWAP may be an idle threat.
But who knows. Maybe the whole thing was designed to be called off, leaving Lind with it all and then moving on with whomever LT wants, or is working with.
No matter, it's out of Bioasis shareholder hands.
jd